Abbott Faces Senate Probe Tying Formula Shortage to Stock Buyback
- Wyden says he’s concerned about high profits, low tax rates
- Key Senate Democrat questions investments into formula plant
This article is for subscribers only.
Senate Finance Committee Chairman Ron Wyden is investigating embattled drugmaker and formula producer Abbott Laboratories’ low tax rates and alleging the company’s investments in stock buybacks may have driven the nationwide baby formula shortage.
Wyden, in a letter to Abbott Chief Executive Officer Robert Ford, highlighted the company’s tax rate -- which has averaged 12% over the past three years -- and $8 billion in stock buybacks in recent years.